Saturday, August 21, 2021
Radio New Zealand/ BBC
Radio New Zealand/ Soutik Biswas for the BBC
The three-dose ZyCoV-D vaccine prevented symptomatic disease in 66 percent of those vaccinated, according to an interim study quoted by the vaccine maker Cadila Healthcare.
The firm plans to make up to 120 million doses of India's second home-grown vaccine every year.
Previous DNA vaccines have worked well in animals but not humans.
India has so far given more than 570 million doses of three previously approved vaccines - Covishield, Covaxin and Sputnik V.
About 13 percent of adults have been fully vaccinated and 47 percent have received at least one shot since the beginning of the drive in January.
Cadila Healthcare said it had conducted the largest clinical trial for the vaccine in India so far, involving 28,000 volunteers in more than 50 centres.
This is also the first time, the firm claimed, a Covid-19 vaccine had been tested in young people in India - 1000 people belonging to the 12-18 age group. The jab was found to be "safe and very well tolerated" in this age group.
The key third phase of clinical trials was conducted at the peak of the deadly second wave of the virus. The vaccine maker believes this reaffirmed the jab's "efficacy against the mutant strains", especially the highly infectious Delta variant.
"I am quite excited about the vaccine because it offers a lot of good potential. If this jab works, the future of vaccination becomes logistically simpler," said Prof Shahid Jameel, a well-known virologist.
How does this vaccine work?
DNA and RNA are building blocks of life. They are molecules that carry that genetic information which are passed on from parents to children.
Like other vaccines, a DNA vaccine, once administered, teaches the body's immune system to fight the real virus.
ZyCoV-D uses plasmids or small rings of DNA, that contain genetic information, to deliver the jab between two layers of the skin.
The plasmids carry information to the cells to make the "spike protein", which the virus uses to latch on and enter human cells.
Most Covid-19 vaccines work by giving the body instructions to make a fragment of the spike protein so it can trigger a person's immune system to produce antibodies and teach itself to fight off the virus.
What makes this vaccine difference?
This is the world's first human DNA vaccine against Covid-19.
There are a number of DNA vaccines approved in the US, for example, for use in animals, including a vaccine for a disease in horses and a skin cancer vaccine for dogs.
However, more than 160 different DNA vaccines are being tested in human clinical trials in the US. Most are devoted to treating existing cancers, and a third of the vaccines were for treating HIV.
ZyCov-D is also India's first needle-free Covid-19 jab.
It is administered with a disposable needle-free injector, which uses a narrow stream of the fluid to penetrate the skin and deliver the jab to the proper tissue.
"To have a DNA vaccine which works against an infection is a big deal. If it gives good protection this is something India will be proud of," said Dr Gagandeep Kang, a virologist and the first Indian woman to be elected Fellow of the Royal Society of London.
What are the advantages of a DNA vaccine?
Scientists say DNA vaccines are relatively cheap, safe and stable.
They can also be stored at higher temperatures from 2C to 8C.
Cadila Healthcare claims that their vaccine had shown "good stability" at 25C for at least three months - this would help the vaccine to be transported and stored easily.
What are the drawbacks of a DNA vaccine?
DNA vaccines developed for infectious diseases in humans have failed in the past.
"The problem is they work well in animals. But they don't end up offering the same level of immune response protection in humans," Dr Kang said.
The challenge, according to Dr Kang, was how to push the plasmid DNA into the human cell so that it gives a durable immune response.
Dr Jeremy Kamil, a virologist at Louisiana State University Health Sciences Center in Shreveport, echoed a similar sentiment.
"Plasmid DNA vaccines have been tried in the past. But we know it's very difficult to get plasmid DNA into the nucleus of human cells, especially in adults," Dr Kamil said.
mRNA vaccines - which use messenger RNA, a molecule, to make the proteins - like Pfizer or Moderna do not need to reach the nucleus of the cell to be effective and offer higher efficacy and are likely to produce longer lasting immunity.
The other potential drawback is that ZyCoV-D requires three doses, instead of two for the other two candidates being used in India. The vaccine maker says it is evaluating at a two-dose jab.
"I would be delighted that a vaccine company overcame the immense challenges to make it work. But it's imperative that the efficacy data be vetted independently," Dr Kamil said.